David A. Siegel Xenon Pharmaceuticals Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 95,300 shares of XENE stock, worth $4.02 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
95,300
Previous 298,800
68.11%
Holding current value
$4.02 Million
Previous $10 Million
70.25%
% of portfolio
0.01%
Previous 0.02%
Shares
25 transactions
Others Institutions Holding XENE
# of Institutions
221Shares Held
72.7MCall Options Held
336KPut Options Held
309K-
Avoro Capital Advisors LLC New York, NY5.4MShares$228 Million3.08% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.34MShares$183 Million1.31% of portfolio
-
Braidwell LP Stamford, CT3.61MShares$152 Million6.91% of portfolio
-
Janus Henderson Group PLC London, X03.58MShares$151 Million0.06% of portfolio
-
Capital International Investors Los Angeles, CA3.18MShares$134 Million0.02% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.63B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...